

Recombinant SARS-CoV-2 Beta Spike RBD Protein [rFc]-K417N

Cat. No.: VReP-GCY072
This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

SARS-CoV-2, Recombinant Protein, Beta, variant B.1.351, Spike RBD Protein, K417N

SPECIFICATIONS

Source	HEK293 Cells
Target	SARS-CoV-2
Type	Viral Antigens
Applications	Used for immunoassays.
Formulation	Sterile PBS, pH 7.4.
Purity	>95% pure by SDS-PAGE.
Product Form	Lyophilized
Storage	Store at -20°C to -80°C.
Introduction	The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.

Alternative Names	2019 novel coronavirus; SARS-CoV-2; Coronaviridae